Author

B. Bornhauser

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Assay:bulk RNA-seq· 1 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Cavalli· 1 shared A. G. Volk· 1 shared A. Hierlemann· 1 shared A. J. Arribas· 1 shared A. Kaestli· 1 shared A. Lupia· 1 shared A. M. Carrasco del Amor· 1 shared A. Stathis· 1 shared

Activity by Year

2018-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Cavalli

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

A first-in-class Wiskott-Aldrich syndrome protein (WASp) activator with anti-tumor activity in hematological cancers

F. Spriano, G. Sartori, L. Barnabei, A. J. Arribas, M. Guala, A. M. Carrasco del Amor, M. R. Tomasso, C. Tarantelli, L. Cascione, G. Golino, M. E. Riveiro, R. Bortolozzi, A. Lupia, F. Paduano, S. Huguet, , E. Gaudio

This paper develops EG-011, a first-in-class WASp activator with anti-tumor activity in hematological cancers, including resistant models.

bioRxiv · Nov 25, 2022 · PreprintCancer Biology

Microphysiological Drug-Testing Platform For Identifying Responses To Prodrug Treatment In Primary Leukemia

F. Gokce, A. Kaestli, C. Lohasz, M. de Geus, H. M. Kaltenbach, K. Renggli, B. Bornhauser, A. Hierlemann, M. M. Modena

The paper develops a microphysiological platform to test prodrug responses in leukemia samples, identifying sample-specific sensitivities to ifosfamide.

bioRxiv · Apr 6, 2022Bioengineering

USP7 cooperates with NOTCH1 to drive the oncogenic transcriptionalprogram in T cell leukemia

P. Ntziachristos, K. Arcipowski, Q. Jin, C. A. Martinez, Y. Zhu, B. T. Gutierrez Diaz, K. Wang, M. Johnson, A. G. Volk, F. Wang, J. wu, H. Wang, I. Sokirniy, P. Thomas, Y. A. Goo, , J. D Crispino

This study identifies USP7 as a key driver of T-cell leukemia by stabilizing NOTCH1 and JMJD3, showing USP7 inhibition blocks leukemia growth and suggests it as a therapeutic target.

bioRxiv · Jan 16, 2018Cancer Biology